New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:28 EDTRHHBY, ABT, JNJ, LH, DHR, DGXCLFS review potential negative for Quest, LabCorp, says Piper Jaffray
Piper Jaffray views the Centers for Medicare & Medicaid Services' plan to revalue Clinical Lab Fee Schedule test codes as a potential negative for Quest Diagnostics (DGX) and LabCorp (LH) as well as diagnostic manufacturers like Abbott (ABT), Danaher (DHR), Johnson & Johnson (JNJ) and Roche (RHHBY). Piper says Quest and LabCorp both have around 12% of revenue exposure to CLFS, which it feels presents risk for additional reimbursement pressure in FY15. The review follows an Office of Inspector General report that found CMS paid between 18%-30% higher for 20 high volume/high expenditure tests than state and federal plans.
News For DGX;LH;ABT;DHR;JNJ;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
January 28, 2016
11:33 EDTABTOptions with increasing call volume
Subscribe for More Information
11:18 EDTLHOptions with increasing put volume
Options with increasing put volume: DRII SNE LH CAVM KSS UCO ILMN JBLU AVT SWK JNPR RRC CL HES
10:47 EDTABTAbbott weakness a buying opportunity, says Deutsche Bank
Subscribe for More Information
10:05 EDTLHHigh option volume stocks
Subscribe for More Information
09:38 EDTABTAbbott says 'definitely not inactive' on M&A
09:38 EDTABTAbbott: Would look at deal 'if it was the right opportunity at the right place'
Says capital allocation priorities have not changed. Regarding M&A, says has been looking at properties "largely internationally." Says has made good deals in the past. Says "We don't see a lot that people are offering up for sale," says prices for things up for sale "imprudent." Says would look at a deal if "it was the right opportunity at the right place." Says "everybody's in the same environment." Says "probably more focused" on M&A.
09:26 EDTABTAbbott sees global diagnostics sales up mid single digits for Q1, FY16
Subscribe for More Information
09:19 EDTABTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Facebook (FB), up 13.9%... Under Armour (UA), up 14.6%... MicroStrategy (MSTR), up 8.9%... Harley-Davidson (HOG), up 8%... Paypal (PYPL), up 6%... Mellanox (MLNX), up 7.9%... Cirrus Logic (CRUS), up 6.2%... Alibaba (BABA), up 4.5%. ALSO HIGHER: Neos Therapeutics (NEOS), up 61.4% after the FDA approved Adzenys XR-ODT for the treatment of ADHD... Exelixis (EXEL), up 4.7% after the U.S. FDA determined the company's New Drug Application for cabozantinib is sufficiently complete... Kinder Morgan (KMI), up 6.7% after being upgraded at Credit Suisse and Stifel. DOWN AFTER EARNINGS: OSI Systems (OSIS), down 21.3%... ServiceNow (NOW), down 22.3%... eBay (EBAY), down 11.5%... InvenSense (INVN), down 10.5%... Juniper Networks (JNPR), down 9.3%... Hologic (HOLX), down 4.4%... Abbott Laboratories (ABT), down 3.6%... Potash (POT), down 2.1%... Qualcomm (QCOM), down 3.6%.
09:19 EDTABTAbbott expects EPS to progressively accelerate throughout 2016
Subscribe for More Information
07:35 EDTABTAbbott sees Q1 EPS ex-items 38c-40c, consensus 47c
Subscribe for More Information
07:34 EDTABTAbbott sees FY16 EPS ex-items $2.10-$2.20, consensus $2.26
Subscribe for More Information
07:33 EDTABTAbbott reports Q4 adjusted EPS 62c, consensus 61c
Subscribe for More Information
06:49 EDTDGXQuest Diagnostics raises quarterly dividend to 40c per share from 38c per share
Quest Diagnostics' board authorized a 5% increase in its quarterly dividend from 38c to 40c per share, or $1.60 per share annually, payable on April 20, to shareholders of record of Quest Diagnostics common stock on April 6.
06:48 EDTDGXQuest Diagnostics sees FY16 adjusted EPS $5.02-$5.17, consensus $5.09
Sees FY16 revenue $7.52B-$7.59B, consensus $7.58B.
06:47 EDTDGXQuest Diagnostics reports Q4 adjusted EPS $1.19, consensus $1.19
Reports Q4 revenue $1.85B, consensus $1.85B.
05:48 EDTRHHBYRoche expects 2016 sales to grow low- to mid-single digit
Subscribe for More Information
05:48 EDTRHHBYRoche board recommends dividend increase to CHF 8.10 per share
Subscribe for More Information
05:47 EDTRHHBYRoche reports FY15 core EPS CHF 13.49 vs. CHF 14.29 last year
05:46 EDTRHHBYRoche reports FY15 Group sales CHF 44.15B vs. CHF 47.46B last year
Subscribe for More Information
05:37 EDTRHHBYAbbVie announces venetoclax granted Breakthrough Therapy Designation by FDA
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use